GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (OSTO:GENO) » Definitions » Cyclically Adjusted PS Ratio

Genovis AB (OSTO:GENO) Cyclically Adjusted PS Ratio : 19.73 (As of Jun. 03, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Genovis AB Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Genovis AB's current share price is kr25.45. Genovis AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was kr1.29. Genovis AB's Cyclically Adjusted PS Ratio for today is 19.73.

The historical rank and industry rank for Genovis AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:GENO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.45   Med: 50.68   Max: 135.83
Current: 20.15

During the past years, Genovis AB's highest Cyclically Adjusted PS Ratio was 135.83. The lowest was 9.45. And the median was 50.68.

OSTO:GENO's Cyclically Adjusted PS Ratio is ranked worse than
83.47% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs OSTO:GENO: 20.15

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genovis AB's adjusted revenue per share data for the three months ended in Mar. 2025 was kr0.493. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr1.29 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genovis AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Genovis AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB Cyclically Adjusted PS Ratio Chart

Genovis AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.64 109.34 53.17 47.56 19.58

Genovis AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.09 23.97 22.22 19.58 14.53

Competitive Comparison of Genovis AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Genovis AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovis AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovis AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genovis AB's Cyclically Adjusted PS Ratio falls into.


;
;

Genovis AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genovis AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=25.45/1.29
=19.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovis AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Genovis AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.493/132.8245*132.8245
=0.493

Current CPI (Mar. 2025) = 132.8245.

Genovis AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.143 99.995 0.190
201509 0.091 100.228 0.121
201512 0.093 100.276 0.123
201603 0.103 100.751 0.136
201606 0.118 101.019 0.155
201609 0.084 101.138 0.110
201612 0.100 102.022 0.130
201703 0.087 102.022 0.113
201706 0.099 102.752 0.128
201709 0.088 103.279 0.113
201712 0.116 103.793 0.148
201803 0.104 103.962 0.133
201806 0.140 104.875 0.177
201809 0.146 105.679 0.184
201812 0.167 105.912 0.209
201903 0.189 105.886 0.237
201906 0.182 106.742 0.226
201909 0.385 107.214 0.477
201912 0.203 107.766 0.250
202003 0.175 106.563 0.218
202006 0.237 107.498 0.293
202009 0.217 107.635 0.268
202012 0.303 108.296 0.372
202103 0.240 108.360 0.294
202106 0.298 108.928 0.363
202109 0.240 110.338 0.289
202112 0.642 112.486 0.758
202203 0.498 114.825 0.576
202206 0.322 118.384 0.361
202209 0.351 122.296 0.381
202212 0.393 126.365 0.413
202303 1.089 127.042 1.139
202306 0.450 129.407 0.462
202309 0.461 130.224 0.470
202312 0.417 131.912 0.420
202403 0.612 132.205 0.615
202406 0.450 132.716 0.450
202409 0.502 132.304 0.504
202412 0.427 132.987 0.426
202503 0.493 132.825 0.493

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genovis AB  (OSTO:GENO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Genovis AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Genovis AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genovis AB Business Description

Industry
Traded in Other Exchanges
Address
Kavlinge, Box 4, Lund, SWE, SE-24421
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.

Genovis AB Headlines

No Headlines